• ANTA SHARMA Maharishi Arvind Institute of Pharmacy, Jaipur 302020, Rajasthan, India
  • SONIKA TANWAR Maharishi Arvind Institute of Pharmacy, Jaipur 302020, Rajasthan, India
  • RAJESH ASIJA Maharishi Arvind Institute of Pharmacy, Jaipur 302020, Rajasthan, India
  • RICHA AGARWAL Maharishi Arvind Institute of Pharmacy, Jaipur 302020, Rajasthan, India



Covid-19, SARS-CoV-2, Fungal infections, Mucormycosis, Aspergillosis, Cryptococcosis


To study fungal infections such as Mucormycosis, Aspergillosis, Candidiasis, Cryptococcosis associated with Covid-19.

A detailed study was done with the information gathered from the articles in specified databases, online sources, and online published materials to have current details of the situation of fungal infections in covid patients.

Fungal infections were seen among covid-19 patients mostly due to opportunistic fungal pathogens such as Mucor, Candida, Aspergillus, and Cryptococcus. The reason behind rising opportunistic fungal infections among covid-19 patients may be the immunocompromised host. The most common species responsible for fungal infections in covid-19 were noticed to be of genus Mucor, A. flavus, and A. fumigatus species of genus Aspergillus, C. albicans species of genus Candida, C. neoformans, and C. gattii species of genus Cryptococcus.

Patients suffering or recovered from covid-19 are now facing numerous Secondary Infections. The majority of secondary infections associated with covid-19 are Fungal Infections. Mucormycosis, candidiasis, aspergillosis, cryptococcosis as opportunistic infections are seen widely in the covid-19 treated patients. Rapid progression of such fungal infections is required to be controlled by early diagnosis of infection and by identifying the underlying risk parameters. Protocols for disease management will be beneficial too.


Download data is not yet available.


Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China. Mycopathologia. 2020 Jul:1-8.

Kaushik K, Agarwal S. The role of Herbal antifungal agents for the management of fungal diseases: A systemic review. Asian J Pharm Clin Res. 2019;12:34-40.

Lai CC, Yu WL. COVID-19 associated with pulmonary Aspergillosis: a literature review. J Microbiol Immunol Infect. 2021;54(1):46-53. doi: 10.1016/j.jmii.2020.09.004.

Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021;135(5):442-7. doi: 10.1017/S0022215121000992.

Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital Mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021;82:1-4.

Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases. 2021;12(3):85-9. doi: 10.14740/jmc3637.

McDonald PJ. Author, Chandrasekar PH chief Editor. Mucormycosis (Zygomycosis) [Internet]. Medscape; 2018. p. 10.

Covid A. 19 Pandemic, India reports over 11,700 black fungus cases Check state-wise report on Mucormycosis cases here. Jagran Engl; 2021.

Coronavirus India Tracker: state-wise Covid-19 cases. Decanherald. Available from: [Last accessed on 25 May 2021]

Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? Lancet Respir Med. 2021 Jun;9(8). doi: 10.1016/S2213-2600(21)00265-4.

Prakash H, Chakrabarti A. Epidemiology of mucormycosis in India. Microorganisms. 2021;9(3):523. doi: 10.3390/microorganisms9030523.

Evidence-based advisory in the time of COVID-19 (screening, diagnosis and management of mucormycosis); 2021. Available from: [Last accessed on 05 Jun 2021]

Zakaria A, Osman M, Dabboussi F, Rafei R, Mallat H, Papon N, Bouchara JP, Hamze M. Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of resistance in clinical Aspergillus species: A general review with a special focus on the Middle Eastern and North African region. J Infect Public Health. 2020;13(1):1-10. doi: 10.1016/j.jiph.2019.08.007.

Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, Klimko N, Lass-Flörl C, Oladele RO, Vinh DC, Zhu L, Boll B, Bruggemann R, Gangneux J, Perfect JR, Patterson TF, Persigehl T, Meis JF, Ostrosky-Zeichner L, White PL, Verweij PE, Cornely OA. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21(6):e149-62. doi: 10.1016/S1473-3099(20)30847-1.

Mohamed A, Rogers TR, Talento AF. COVID-19 associated invasive pulmonary aspergillosis: diagnostic and therapeutic challenges. JoF. 2020;6(3):115. doi: 10.3390/jof6030115.

Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P, Krause R, Cornely OA, Perlin S. COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment. J Fungi 2020;6:91.

Riad A, Gomaa E, Hockova B, Klugar M. Oral candidiasis of COVID-19 patients: case report and review of the evidence. J Cosmet Dermatol. 2020;20:1580-4.

Arya NR, Naureen BR. Candidiasis [internet]; 2021. Stat Pearls. Available from: https: candidiasis-statpearls-NCBIbookshelf ( [Last accessed on 16 Jun 2021]

Isalkar U. Don’t call Candida-linked infections white fungus. The times of India: Forthcoming; 2021.

Pfaller MA. Epidemiology of candidiasis. J Hosp Infect. 1995;30:329-38. doi: 10.1016/0195-6701(95)90036-5.

Fu J, Ding Y, Wei B, Wang L, Xu S, Qin P, Wei L, Jiang L. Epidemiology of Candida albicans and non-C. albicans of neonatal candidemia at a tertiary care hospital in western China. BMC Infect Dis. 2017;17(1):329. doi: 10.1186/s12879-017-2423-8.

Traci C, Johnson MD. What is candidiasis? [internet]; 2020. WebMD. Available from: [Last accessed on 23 Jun 2021]

Rajendra Santosh ABJ, Muddana K, Bakki SR. Fungal infections of oral cavity: diagnosis, management, and association with COVID-19. SN Compr Clin Med 2021;3(6):1373-84. doi: 10.1007/s42399-021-00873-9.

Abohelwa MM, Rio-Pertuz GD, Parmar KN, Morataya C, Siddique S, Duangkham S, Nugent KM. Pulmonary cryptococcosis in the 2019 novel coronavirus, when the coinfection affects the mortality. Am J Respir Crit Care Med. 2021;203:2461.

Bhattacharya S, Banerjee A. Cryptococcosis in an advance state of aids and its challenging therapeutic regimen: is it really curable? Asian J Pharm Clin Res. 2015;8:51-3.

Outlookindia. Available from: https://www.outlookindia. [Last accessed on 24 Jun 2021]

Hughes S, Troise O. Oral candidiasis: causes, types, and treatment. Pharm J. 2020 Nov;305(7943).

White Fungus. Available from: [Last accessed on 24 Jun 2021]

Why are the fungal infections named after colours-Black, white and yellow? Read here. Available from: https://www.mumbailive. [Last accessed on 24 Jun 2021]

Decoding the Mysterious yellow fungus; experts call for genetic testing; c2021. Available from: [Last accessed on 01 Sep 2021]

Randhawa HS, Kowshik T, Preeti Sinha K, Chowdhary A, Khan ZU, Yan Z, Xu J, Kumar A. Distribution of Cryptococcus gattii and Cryptococcus neoformans in decayed trunk wood of Syzygium cumini trees in north-western India. Med Mycol. 2006;44(7):623-30. doi: 10.1080/13693780600860946. [Internet]. Aspergillus fumigatus; c2018. Available from: https://alchetron. com/Aspergillus-fumigatus. [Last accessed on 25 Jun 2021] [Internet]. India’s first case of ‘green fungus’ infection reported in Madhya Pradesh: All you need to know; c2021. Available from: [Last accessed on 24 Jun 2021]. [Internet]. What is Green fungus: key things to know; c2021. Available from:,medicine%20HoD%20Dr%20Ravi%20Dosi. [Last accessed on 24 Jun 2021].



How to Cite

SHARMA, A., S. TANWAR, R. ASIJA, and R. AGARWAL. “FUNGAL INFECTIONS ASSOCIATED WITH COVID-19”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 13, no. 10, Oct. 2021, pp. 12-19, doi:10.22159/ijpps.2021v13i10.42554.



Review Article(s)